-- ハンソウ・ファーマシューティカル（香港証券取引所：3692）の注射剤HS-20093（アデブレリマブとの併用）が、中国国家薬品監督管理局より画期的治療薬指定医薬品（Breakthrough Therapy Designated Drug）として承認されたことが、木曜日に香港証券取引所に提出された書類で明らかになった。 この承認は、局所進行性または転移性の非小細胞肺がんの適応症に関するものである。
Related Articles
Research
Update: Chardan Initiates Riot Platforms at Buy With $27.50
Riot Platforms (RIOT) has an average rating of buy and mean price target of $26.58, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$RIOT
Research
JPMorgan Initiates Coverage on Matson With Overweight Rating, $230 Price Target
Matson (MATX) has an average rating of Buy and mean price target of $220, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$MATX
Research
Chardan Initiates Keel Infrastructure at Buy With $4.50 Price Target
$KEEL